Tímea Tünde Takács, Rita Magyar-Stang, Szabolcs Szatmári, Ildikó Sipos, Katalin Saftics, Ádám József Berki, Sándor Évin, Dániel Bereczki, Csaba Varga, Nóra Nyilas, István Bíró, Péter Barsi, Máté Magyar, Pál Maurovich-Horvat, Péter Pál Böjti, Máté Pásztor, István Szikora, Sándor Nardai, Bence Gunda
{"title":"Workload and clinical impact of MRI-based extension of reperfusion therapy time window in acute ischaemic stroke—a prospective single-centre study","authors":"Tímea Tünde Takács, Rita Magyar-Stang, Szabolcs Szatmári, Ildikó Sipos, Katalin Saftics, Ádám József Berki, Sándor Évin, Dániel Bereczki, Csaba Varga, Nóra Nyilas, István Bíró, Péter Barsi, Máté Magyar, Pál Maurovich-Horvat, Péter Pál Böjti, Máté Pásztor, István Szikora, Sándor Nardai, Bence Gunda","doi":"10.1007/s11357-025-01549-1","DOIUrl":null,"url":null,"abstract":"<p>Current European Stroke Organisation (ESO) guidelines recommend extended time window reperfusion therapies (4.5–9 h for thrombolysis, 6–24 h for thrombectomy) based on advanced imaging. However, the workload and clinical benefit of this strategy on a population basis are not known. To determine the caseload, treatment rates, and outcomes in the extended as compared to the standard time windows. All consecutive ischaemic stroke patients within 24 h of last known well between 1st March 2021 and 28th February 2022 were included in a prospective single-centre study. Treatment eligibility in the extended time windows or wake-up strokes recognized within 4 h was based on current ESO guideline criteria using MRI DWI-PWI or DWI-FLAIR mismatch. MRI was only available during working hours (8–20 h); otherwise, CT/CTA was used. Clinical outcome in treated patients was assessed at three months. Among the 777 admitted patients, 252 (32.4%) had MRI. The thrombolysis rate was 119/304 (39.1%) in standard and 14/231 (6.1%) in the extended time window. The thrombectomy rate was 34/386 (8.8%) in standard and 15/391 (3.8%) in the extended time window. Independent clinical outcomes (mRS ≤ 2) were not statistically different in early and late-treated patients both for thrombolysis (48% vs. 28.6%, <i>p</i> = 0.25) and thrombectomy (38.4% vs. 33.3%, <i>p</i> = 0.99). Even with a limited availability of advanced imaging extending therapeutic time windows resulted in an 11.7% increase in thrombolysis and a 44% increase in thrombectomy with comparable clinical outcomes in early and late-treated patients at the price of a twofold burden in clinical and advanced imaging screening.</p>","PeriodicalId":12730,"journal":{"name":"GeroScience","volume":"40 1","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"GeroScience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11357-025-01549-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Current European Stroke Organisation (ESO) guidelines recommend extended time window reperfusion therapies (4.5–9 h for thrombolysis, 6–24 h for thrombectomy) based on advanced imaging. However, the workload and clinical benefit of this strategy on a population basis are not known. To determine the caseload, treatment rates, and outcomes in the extended as compared to the standard time windows. All consecutive ischaemic stroke patients within 24 h of last known well between 1st March 2021 and 28th February 2022 were included in a prospective single-centre study. Treatment eligibility in the extended time windows or wake-up strokes recognized within 4 h was based on current ESO guideline criteria using MRI DWI-PWI or DWI-FLAIR mismatch. MRI was only available during working hours (8–20 h); otherwise, CT/CTA was used. Clinical outcome in treated patients was assessed at three months. Among the 777 admitted patients, 252 (32.4%) had MRI. The thrombolysis rate was 119/304 (39.1%) in standard and 14/231 (6.1%) in the extended time window. The thrombectomy rate was 34/386 (8.8%) in standard and 15/391 (3.8%) in the extended time window. Independent clinical outcomes (mRS ≤ 2) were not statistically different in early and late-treated patients both for thrombolysis (48% vs. 28.6%, p = 0.25) and thrombectomy (38.4% vs. 33.3%, p = 0.99). Even with a limited availability of advanced imaging extending therapeutic time windows resulted in an 11.7% increase in thrombolysis and a 44% increase in thrombectomy with comparable clinical outcomes in early and late-treated patients at the price of a twofold burden in clinical and advanced imaging screening.
目前欧洲卒中组织(ESO)指南推荐基于先进成像的延长时间窗再灌注治疗(溶栓4.5-9小时,取栓6-24小时)。然而,这种策略在人群基础上的工作量和临床效益尚不清楚。确定与标准时间窗相比,延长时间窗内的病例量、治疗率和结果。所有在2021年3月1日至2022年2月28日24小时内已知的连续缺血性卒中患者纳入前瞻性单中心研究。延长时间窗口或4小时内识别的醒脑卒中的治疗资格基于当前ESO指南标准,使用MRI DWI-PWI或DWI-FLAIR不匹配。MRI仅在工作时间(8-20小时)进行;否则行CT/CTA检查。治疗患者的临床结果在3个月时进行评估。在777例住院患者中,有252例(32.4%)进行了MRI检查。标准溶栓率为119/304(39.1%),延长时间窗溶栓率为14/231(6.1%)。标准时间窗取栓率为34/386(8.8%),延长时间窗取栓率为15/391(3.8%)。早期和晚期溶栓(48% vs. 28.6%, p = 0.25)和取栓(38.4% vs. 33.3%, p = 0.99)患者的独立临床结局(mRS≤2)无统计学差异。即使先进影像的可用性有限,延长治疗时间窗口导致早期和晚期治疗患者溶栓率增加11.7%,取栓率增加44%,临床结果相当,但代价是临床和先进影像筛查的双重负担。
GeroScienceMedicine-Complementary and Alternative Medicine
CiteScore
10.50
自引率
5.40%
发文量
182
期刊介绍:
GeroScience is a bi-monthly, international, peer-reviewed journal that publishes articles related to research in the biology of aging and research on biomedical applications that impact aging. The scope of articles to be considered include evolutionary biology, biophysics, genetics, genomics, proteomics, molecular biology, cell biology, biochemistry, endocrinology, immunology, physiology, pharmacology, neuroscience, and psychology.